BOSTON, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter and fiscal year ended ...

Received $350 Million in upfront cash at closing; Up to $425 Million in total proceeds inclusive of near-term earnout payments Approximately $550 Million in cash & cash equivalents on balance sheet at ...

As of Wednesday, February 25, Standard BioTools Inc.’s LAB share price has surged by 6.52%, which has investors questioning ...

CEO Michael Egholm highlighted that Standard BioTools delivered Q1 2025 revenues of $40.8 million, aligned with their plan despite a challenging operating backdrop. He emphasized improvements in ...

Standard BioTools reports preliminary 2024 revenue of $174 million and will present at the J.P. Morgan Healthcare Conference. Standard BioTools Inc. announced preliminary, unaudited revenue results ...

Illumina is diving deeper into proteomics research with a $425 million plan to acquire SomaLogic, including its protein analysis platforms and certified lab services business. The deal with ...

BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today announced preliminary and unaudited revenue results for the fourth quarter ...

Recommendations Reiterate that Value Maximizing Transaction Is in the Best Interests of Stockholders; Board Urges Stockholders to Vote "FOR" the Transaction BOULDER, Colo., Dec. 29, 2023 /PRNewswire/ ...

SOUTH SAN FRANCISCO, Calif. (AP) — SOUTH SAN FRANCISCO, Calif. (AP) — Standard BioTools Inc. (LAB) on Tuesday reported a loss of $34.7 million in its third quarter. On a per-share basis, the South San ...

Standard BioTools Inc. will release its first quarter 2025 financial results on May 6, 2025, after market close, and will host a conference call and webcast at 4:30 p.m. ET that same day to discuss ...